Skip to content

US · JSPR · BIOTECHNOLOGY

Jasper Therapeutics, Inc. (JSPR) intrinsic value and stock valuation

$8.69as of 2026-11-21 · Mkt cap 10.73M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Jasper Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values JSPR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from JSPR’s statements →

Jasper Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Redwood City, CA 94065 jaspertx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-75.8M
20192025
Free cash flow
-$-77.17M
20192025
Total equity
$4.15M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-80.52M-$-76.24M-$-68.86M-$-51.2M-$-36.83M
Net income-$-75.8M-$-71.27M-$-64.47M-$-37.69M-$-30.64M
EPSd-$-4.94M-$-4.89M-$-6.18M-$-10.33M-$-26.88M
Operating cash flow-$-77.16M-$-62.6M-$-52.07M-$-45.86M-$-33.68M
Capital expenditure-$-10K-$-550K-$-270K-$-580K-$-2.43M
Free cash flow-$-77.17M-$-63.15M-$-52.33M-$-46.43M-$-36.11M
Total assets$35.8M$79.9M$94.9M$48.4M$93.7M
Total debt$1.24M$1.81M$2.79M$3.65M$2.88M
Net debt-$-27.46M-$-69.82M-$-84.1M-$-34.6M-$-81.82M
Total equity$4.15M$61.7M$78.4M$36M$69.5M
Cash and short-term investments$28.7M$71.6M$86.9M$38.3M$84.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$1.06M$0.00$0.00$0.00$0.00
Gross profit-$-1.06M$0.00$0.00$0.00$0.00
Research and development expenses$60.5M$55.8M$51.8M$34.6M$25.4M
Selling, general and administrative expenses$18.9M$20.4M$17.1M$16.6M$11.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$79.5M$76.2M$68.9M$51.2M$36.8M
Cost and expenses$80.5M$76.2M$68.9M$51.2M$36.8M
Interest income$1.74M$5.06M$5.2M$700K$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.06M$1.37M$1.11M$970K$380K
Ebitda-$-74.75M-$-69.9M-$-63.36M-$-36.71M-$-30.26M
Operating income-$-80.52M-$-76.24M-$-68.86M-$-51.2M-$-36.83M
Total other income/expenses, net$4.72M$4.97M$4.4M$13.5M$6.2M
Income before tax-$-75.8M-$-71.27M-$-64.47M-$-37.69M-$-30.64M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-75.8M-$-71.27M-$-64.47M-$-37.69M-$-30.64M
Weighted average shares outstanding$19.2M$14.6M$10.4M$3.65M$1.14M
Weighted average diluted shares outstanding$15.3M$14.6M$10.4M$3.65M$1.14M
Balance sheet
20252024202320222021
Cash and short-term investments$28.7M$71.6M$86.9M$38.3M$84.7M
Net receivables$0.00$0.00$250K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$34.7M$75.8M$88.9M$41.7M$87.8M
Property, plant and equipment, net$600K$2.85M$4.19M$5.45M$4.83M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$420K$420K$0.00$0.00
Total non-current assets$1.13M$4.09M$5.95M$6.63M$5.82M
Total assets$35.8M$79.9M$94.9M$48.4M$93.7M
Accounts payable$6.22M$4.03M$4.15M$1.77M$3.92M
Short-term debt$1.24M$1.09M$970K$860K$510K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$13.2M$15.2M$12.4M$7.07M$8.02M
Long-term debt$0.00$720K$1.81M$2.79M$2.38M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$18.4M$2.99M$4.08M$5.31M$16.1M
Capital lease obligations$1.24M$1.81M$2.79M$3.65M$2.88M
Total liabilities$31.6M$18.2M$16.5M$12.4M$24.1M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-316.67M-$-240.87M-$-169.6M-$-105.14M-$-67.45M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$4.15M$61.7M$78.4M$36M$69.5M
Total investments$0.00$420K$420K$0.00$0.00
Total debt$1.24M$1.81M$2.79M$3.65M$2.88M
Net debt-$-27.46M-$-69.82M-$-84.1M-$-34.6M-$-81.82M
Cash flow statement
20252024202320222021
Net income-$-75.8M-$-71.27M-$-64.47M-$-37.69M-$-30.64M
Depreciation and amortization$1.06M$1.37M$1.11M$1.31M$380K
Stock-based compensation$6.71M$6.62M$5.21M$0.00$1.05M
Change in working capital-$-4.92M$170K$5.1M-$-650K$1.62M
Accounts receivable$0.00$0.00$660K-$-660K$600K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.19M-$-120K$2.38M-$-2.15M$2.94M
Net cash provided by operating activities-$-77.16M-$-62.6M-$-52.07M-$-45.86M-$-33.68M
Investments in property, plant and equipment-$-10K-$-550K-$-270K-$-580K-$-2.43M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$10K-$-530K-$-270K-$-580K-$-2.43M
Common stock issued$34.2M$47.2M$101.5M$60K$240K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$34.2M$47.9M$101M$60K$101M
Net change in cash-$-42.95M-$-15.25M$48.6M-$-46.45M$64.9M
Cash at end of period$29.1M$72.1M$87.3M$38.3M$85.1M
Operating cash flow-$-77.16M-$-62.6M-$-52.07M-$-45.86M-$-33.68M
Capital expenditure-$-10K-$-550K-$-270K-$-580K-$-2.43M
Free cash flow-$-77.17M-$-63.15M-$-52.33M-$-46.43M-$-36.11M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Jasper Therapeutics, Inc.

        Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

        CEO
        Jeetinder Singh Mahal
        Employees
        22
        Beta
        3.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Jasper Therapeutics, Inc. (JSPR)?

        InvestorsCraft does not currently publish an intrinsic value for JSPR. How the IC value is calculated.

        Is JSPR undervalued?

        InvestorsCraft does not publish an undervaluation signal for JSPR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.